ଡାକୋମିଟିନିବ

ଡାକୋମିଟିନିବ
Clinical data
Pronunciation	dak" oh mi' ti nib
Trade names	Vizimpro
Synonyms	PF-00299804
AHFS/Drugs.com	monograph
MedlinePlus	a618055
data	US DailyMed: Dacomitinib;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	80%
Protein binding	98%
Metabolism	CYP2D6, CYP3A4
Metabolites	O-desmethyl-dacomitinib
Elimination half-life	70 hrs
Excretion	79% faeces, 3% urine
Identifiers
	IUPAC name (2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide;
Chemical and physical data
Formula	C24H25ClFN5O2
Molar mass	୪୬୯.୯୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4;
	InChI InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+; Key:LVXJQMNHJWSHET-AATRIKPKSA-N;

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Dacomitinib

ଡାକୋମିଟିନିବ (ଇଂରାଜୀ ଭାଷାରେ Dacomitinib), ଭିଜିମପ୍ରୋ ଏହାର ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅଣ-ଛୋଟ-ଜୀବକୋଷ ଫୁସଫୁସ କର୍କଟ (NSCLC) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା କେତେକ ଏପିଡର୍ମାଲ୍ ବୃଦ୍ଧି ଫ୍ୟାକ୍ଟର୍ ରିସେପ୍ଟର (EGFR) ମ୍ୟୁଟେସନ ସହିତ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ରାସ, ପାଟି ପ୍ରଦାହ, ନେତ୍ରାବରଣ ପ୍ରଦାହ, ଗଲୁ, ଯକୃତ ସମସ୍ୟା ଏବଂ ଅଇ ହୋଇପାରେ ।^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଇଣ୍ଟରସ୍ଟିସିଆଲ୍ ଫୁସଫୁସ ରୋଗ ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୧] ଏହା ଇଜିଏଫଆର (EGFR)ର ଏକ ଟାଇରୋସିନ୍ କାଇନେଜ ଇନହିବିଟର ।^[୩]

୨୦୧୮ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୧୯ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଡାକୋମିଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ^[୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ମାସକୁ ଏହି ଚିକିତ୍ସା ପିଛା ପ୍ରାୟ ୧୪,୩୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୨୭୦୦ ପାଉଣ୍ଡ ଥିଲା ।^[୫]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ "Dacomitinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 1 January 2022. Retrieved 17 December 2021.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Vizimpro EPAR". European Medicines Agency (EMA). 5 June 2019. Archived from the original on 13 December 2019. Retrieved 13 December 2019.
↑ "Dacomitinib". NCI Drug Dictionary. National Cancer Institute, U.S. Department of Health and Human Services. Archived from the original on 28 April 2015. Retrieved 31 May 2021.
↑ "Vizimpro Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 May 2019. Retrieved 17 December 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1021. ISBN 978-0857114105.

[AHFS2021-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ "Dacomitinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 1 January 2022. Retrieved 17 December 2021.

[EPAR2021-2] ୨.୦ ^୨.୧ ^୨.୨ "Vizimpro EPAR". European Medicines Agency (EMA). 5 June 2019. Archived from the original on 13 December 2019. Retrieved 13 December 2019.

[NCI2021-3] "Dacomitinib". NCI Drug Dictionary. National Cancer Institute, U.S. Department of Health and Human Services. Archived from the original on 28 April 2015. Retrieved 31 May 2021.

[4] "Vizimpro Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 May 2019. Retrieved 17 December 2021.

[BNF81-5] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1021. ISBN 978-0857114105.

[୧]

[୨]

[୩]

[୪]

[୫]